<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H6539D20F8E4542A4A2099AD8397620FD" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2415 IH: To amend the Federal Food, Drug, and Cosmetic Act to provide for establishment of a streamlined data review program.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2415</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150519">May 19, 2015</action-date>
			<action-desc><sponsor name-id="B001248">Mr. Burgess</sponsor> (for himself and <cosponsor name-id="E000179">Mr. Engel</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to provide for establishment of a streamlined
			 data review program.</official-title>
	</form>
	<legis-body id="H83F6411EA5B94F659302AB01A99CDAE0" style="OLC">
		<section id="HD622914D5D3C46BEB9114DE2B0C585C9" section-type="section-one"><enum>1.</enum><header>Streamlined data review program</header>
 <subsection id="HE3D577003FC747E2AEB20359CEF60A91"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by inserting after section 505F of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">21 U.S.C. 355f</external-xref>) the following:</text>
				<quoted-block id="H221FE7B7666F45A9ABE5327364A2F27D" style="OLC">
					<section id="HD16D6468DE8642AFBDFFAF5E7B320CBA"><enum>505F.</enum><header>Streamlined data review program</header>
 <subsection id="H9BF9EDC266C74A38A2D2483D6E1C1A6A"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall establish a streamlined data review program under which a holder of an approved application submitted under section 505(b)(1) or under section 351(a) of the Public Health Service Act may, to support the approval or licensure (as applicable) of the use of the drug that is the subject of such approved application for a new qualified indication, submit qualified data summaries.</text>
 </subsection><subsection id="H1CE64AC27E3E457FB217599D8A2F8CE2"><enum>(b)</enum><header>Eligibility</header><text display-inline="yes-display-inline">In carrying out the streamlined data review program under subsection (a), the Secretary may authorize the holder of the approved application to include one or more qualified data summaries described in subsection (a) in a supplemental application if—</text>
 <paragraph id="H469D7373E56D4FC38446E4F983DEDFD6"><enum>(1)</enum><text>the drug has been approved under section 505(c) of this Act or licensed under section 351(a) of the Public Health Service Act for one or more indications, and such approval or licensure remains in effect;</text>
 </paragraph><paragraph id="HD0FBD5190F124DD2BA043CAEC45E62A2"><enum>(2)</enum><text display-inline="yes-display-inline">the supplemental application is for approval or licensure (as applicable) under such section 505(c) or 351(a) of the use of the drug for a new qualified indication under such section 505(c) or 351(a);</text>
 </paragraph><paragraph id="H88420BBA2F484BD38BB9E5A152BB6C58"><enum>(3)</enum><text display-inline="yes-display-inline">there is an existing database acceptable to the Secretary regarding the safety of the drug developed for one or more indications of the drug approved under such section 505(c) or licensed under such section 351(a);</text>
 </paragraph><paragraph id="HA4DE157429DF433A98BD1C295F95B856"><enum>(4)</enum><text>the supplemental application incorporates or supplements the data submitted in the application for approval or licensure referred to in paragraph (1); and</text>
 </paragraph><paragraph id="H1275867E1C3B4CC2A45CFAAEEB41873C"><enum>(5)</enum><text display-inline="yes-display-inline">the full data sets used to develop the qualified data summaries are submitted, unless the Secretary determines that the full data sets are not required.</text>
 </paragraph></subsection><subsection id="H0F13AD05A1BC4F699272FD391750C89C"><enum>(c)</enum><header>Public availability of information on program</header><text display-inline="yes-display-inline">The Secretary shall post on the public website of the Food and Drug Administration and update annually—</text>
 <paragraph id="H0B775E7AD5824B66A17F7F798F1CE108"><enum>(1)</enum><text>the number of applications reviewed under the streamlined data review program;</text> </paragraph><paragraph id="H6882E9C0E419461C87F89AE0789BDFD2"><enum>(2)</enum><text>the average time for completion of review under the streamlined data review program versus other review of applications for new indications; and</text>
 </paragraph><paragraph id="HABEFAC50176042AE90B65972FE62A958"><enum>(3)</enum><text>the number of applications reviewed under the streamlined data review program for which the Food and Drug Administration made use of full data sets in addition to the qualified data summary.</text>
 </paragraph></subsection><subsection id="H4780E534EB1446818B73586F49E5612C"><enum>(d)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text> <paragraph id="H65319E10A1924C00AADB82508F5B75BC"><enum>(1)</enum><text display-inline="yes-display-inline">The term <quote>qualified indication</quote> means—</text>
 <subparagraph id="H2B311BCAF3834860B98B13115576D511"><enum>(A)</enum><text display-inline="yes-display-inline">an indication for the treatment of cancer, as determined appropriate by the Secretary; or</text> </subparagraph><subparagraph id="HED6698C322B1433C8D84BBE323D1364D"><enum>(B)</enum><text>such other types of indications as the Secretary determines to be subject to the streamlined data review program under this section.</text>
 </subparagraph></paragraph><paragraph id="HA2F68861CD2E4A3CA380BA79129BA415"><enum>(2)</enum><text>The term <quote>qualified data summary</quote> means a summary of clinical data intended to demonstrate safety and effectiveness with respect to a qualified indication for use of a drug.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H1B461A190880433A860AE00C1B36ACA6"><enum>(b)</enum><header>Sense of Congress</header><text display-inline="yes-display-inline">It is the sense of Congress that the streamlined data review program under section 505F of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), should enable the Food and Drug Administration to make approval decisions for certain supplemental applications based on qualified data summaries (as defined in such section 505F).</text>
 </subsection><subsection id="H8BC78AB217FA4D1CB4A6B0B220412CA0"><enum>(c)</enum><header>Guidance; regulations</header><text>The Commissioner of Food and Drugs—</text> <paragraph id="HEC43289B503B42F98AE5FB468DB04129"><enum>(1)</enum><text display-inline="yes-display-inline">shall—</text>
 <subparagraph id="H8A8CEA443A484F59A0F8878395FD16CB"><enum>(A)</enum><text>issue final guidance for implementation of the streamlined data review program established under section 505F of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), not later than 24 months after the date of enactment of this Act; and</text>
 </subparagraph><subparagraph id="H187375A7FF74458690F78824FFA042DE"><enum>(B)</enum><text>include in such guidance the process for expanding the types of indications to be subject to the streamlined data review program, as authorized by section 505F(c)(1)(B) of such Act; and</text>
 </subparagraph></paragraph><paragraph id="H2E812926FED8428AB72BC1F7F7BAC4C5"><enum>(2)</enum><text>in addition to issuing guidance under paragraph (1), may issue such regulations as may be necessary for implementation of the program.</text>
				</paragraph></subsection></section></legis-body>
</bill>


